Exicure, Inc. (NASDAQ:XCUR - Get Free Report) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 27,500 shares, a decline of 19.8% from the March 31st total of 34,300 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily volume of 41,100 shares, the short-interest ratio is currently 0.7 days.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Exicure stock. Geode Capital Management LLC acquired a new stake in shares of Exicure, Inc. (NASDAQ:XCUR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,645 shares of the company's stock, valued at approximately $173,000. Geode Capital Management LLC owned about 0.48% of Exicure at the end of the most recent reporting period. Institutional investors and hedge funds own 42.82% of the company's stock.
Exicure Stock Performance
XCUR stock traded down $0.21 during trading on Wednesday, hitting $10.29. 7,074 shares of the company's stock traded hands, compared to its average volume of 569,798. Exicure has a 52 week low of $1.44 and a 52 week high of $36.00. The stock has a market capitalization of $65.01 million, a price-to-earnings ratio of -4.97 and a beta of 3.86. The business has a fifty day simple moving average of $11.77 and a 200 day simple moving average of $11.65.
Exicure (NASDAQ:XCUR - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) earnings per share (EPS) for the quarter.
About Exicure
(
Get Free Report)
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Recommended Stories
Before you consider Exicure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exicure wasn't on the list.
While Exicure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
